Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Guardant Health Inc
(NQ:
GH
)
18.88
+0.30 (+1.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Guardant Health Inc
< Previous
1
2
3
4
5
Next >
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
April 22, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
April 18, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
April 03, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
March 13, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Guardant Health, Inc.
Via
Business Wire
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
March 01, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
February 22, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
February 15, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
February 01, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
January 17, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
January 08, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
January 08, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
January 02, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
December 21, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
December 19, 2023
From
Guardant Health, Inc.
Via
Business Wire
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
December 04, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
November 30, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Appeal Federal District Court Verdict
November 15, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
November 06, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in Upcoming November Investor Conferences
November 03, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
October 31, 2023
From
Guardant Health, Inc.
Via
Business Wire
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
October 23, 2023
From
Guardant Health, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
October 17, 2023
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
October 16, 2023
From
Guardant Health, Inc.
Via
Business Wire
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
September 26, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The...
Via
FinancialNewsMedia
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
September 06, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
September 05, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
September 01, 2023
From
Guardant Health, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.